Menu
Back to Journals » Lung Cancer: Targets and Therapy » Volume 15
ESCI
SJR OA
CiteScore
Impact Factor
Lung Cancer: Targets and Therapy
ISSN: 1179-2728
- View all (178)
- Volume 15, 2024 (6)
- Volume 14, 2023 (12)
- Volume 13, 2022 (8)
- Volume 12, 2021 (14)
- Volume 11, 2020 (11)
- Volume 10, 2019 (16)
- Volume 9, 2018 (14)
- Volume 8, 2017 (25)
- Volume 7, 2016 (17)
- Volume 6, 2015 (9)
- Volume 5, 2014 (10)
- Volume 4, 2013 (9)
- Volume 3, 2012 (9)
- Volume 2, 2011 (6)
- Volume 1, 2010 (12)
Archive: Volume 15, 2024
Commentary
The Butterfly Flies - Practice Changing Results of PAPILLON, First Line Chemotherapy and Amivantamab for the Treatment of NSCLC Patients with EGFR Exon 20 Insertions
Kaakour D, Nagasaka M
Lung Cancer: Targets and Therapy 2024, 15:49-54
Published Date: 23 April 2024
Commentary
MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting?
Brazel D, Nagasaka M
Lung Cancer: Targets and Therapy 2024, 15:41-47
Published Date: 12 April 2024
Original Research
Effectiveness and Safety of Anlotinib Combined with PD-1 Blockades in Patients with Previously Immunotherapy Treated Advanced Non-Small Cell Lung Cancer: A Retrospective Exploratory Study
Dou XJ, Ma RY, Ren DW, Liu Q, Yan P
Lung Cancer: Targets and Therapy 2024, 15:29-40
Published Date: 25 March 2024
Perspectives
Overcoming Central β-Sheet #6 (Cβ6) ALK Mutation (L1256F), TP53 Mutations and Short Forms of EML4-ALK v3/b and v5a/b Splice Variants are the Unmet Need That a Re-Imagined 5th-Generation (5G) ALK TKI Must Deliver
Lee ATM, Ou SI
Lung Cancer: Targets and Therapy 2024, 15:19-27
Published Date: 27 February 2024
Original Research
Innovative Techniques in Video-Assisted Thoracoscopic Surgery: Lu’s Approach
Wang B, Wang J, Sun T, Ding Y, Li S, Lu H
Lung Cancer: Targets and Therapy 2024, 15:9-17
Published Date: 2 February 2024
Commentary
The Nail in the Coffin?: Examining the KEYNOTE-789 Clinical Trial’s Impact
Arter ZL, Nagasaka M
Lung Cancer: Targets and Therapy 2024, 15:1-8
Published Date: 25 January 2024